Drug intelligence / Profile preview

miR-150-5p mimic-exos

Development stage: Preclinical
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous, Intracranial

Overview

miR-150-5p mimic-exos is an exosome-based therapeutic agent derived from human umbilical mesenchymal stem cells (HUMSCs) that carries microRNA-150-5p (miRNA-150-5p). It is being investigated for its potential to treat rheumatoid arthritis (RA) by alleviating bone destruction and regulating bone immunity. The drug is thought to exert its effects by modulating regulatory T cells (Tregs) and osteoclasts (OCs) through the aryl hydrocarbon receptor (AhR) signaling pathway.

Targets

FNDC5 (Fibronectin type III domain-containing protein 5)FTO (Fat mass and obesity-associated protein)PTEN (Phosphatase and tensin homolog deleted on chromosome ten)Thioredoxin-interacting protein (TXNIP) mRNA

Beyond the preview

Go deeper on miR-150-5p mimic-exos.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-150-5p mimic-exos.

Explore the full profile